American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Horwitz
    Horwitz
  3. Noy
    Noy
  4. Perales
    Perales
  5. Levine
    Levine
  6. Devlin
    Devlin
  7. Palomba
    Palomba
  8. Zelenetz
    Zelenetz
  9. Moskowitz
    Moskowitz
  10. Shah
    Shah

Groups

  1. Center for Hematologic Malignancies (238)
  2. Hematologic Malignancies, Division of (236)
  3. Department of Medicine (235)
  4. Adult Leukemia (105)
  5. GSK Faculty (79)
  6. Lymphoma (71)
  7. Executive Committee, Center for Hematologic Malignancies (67)
  8. Sloan Kettering Institute Postdocs (57)
  9. Bone Marrow Transplant (56)
  10. Survivorship Research (55)
Search Within
  1. "2019"
Formats
  1. Meeting Abstract (238)
  2. Journal Article (46)
  3. Review (4)
  4. Editorial (3)
  5. Guidelines (3)
  6. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (238)
  2. Hematologic Malignancies, Division of (236)
  3. Department of Medicine (235)
  4. Adult Leukemia (105)
  5. GSK Faculty (79)
  6. Lymphoma (71)

More Groups

People
  1. Martin Tallman (31)
  2. Sergio Giralt (25)
  3. Ross Levine (24)
  4. Steven Horwitz (24)
  5. Ariela Noy (22)
  6. Miguel-Angel Perales (21)

More People

Years
  1. 2019 (295)
Publications
  1. Blood (268)
  2. Blood Advances (26)
  3. Hematology-American Society of Hematology Education Program (1)

Results (295)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Aberrant SYK expression as a potential therapeutic target in T/NK cell neoplasms
    Meeting Abstract

    Zhang, J. P.; Gao, Q.; Chan, A.; Xiao, W.; El Daker, S.; Roshal, M.; Dogan, A.
    Blood (2019)

    Fulltext@MSK | Save
  • A phase I study of CC-90002, a monoclonal antibody targeting CD47, in patients with relapsed and/or refractory (R/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS): Final results
    Meeting Abstract

    Zeidan, A. M.; DeAngelo, D. J.; Palmer, J. M.; Seet, C. S.; Tallman, M. S.; Wei, X.; Li, Y. F.; Hock, N.; Burgess, M. R.; Hege, K.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • ME-401-003 (TIDAL): A multicenter, randomized, double-blind, placebo-controlled, two-arm, phase 2 study of ME-401 investigating continuous and intermittent dosing schedules in patients with relapsed/refractory follicular lymphoma
    Meeting Abstract

    Zelenetz, A. D.; Zinzani, P. L. L.; Chan, H.; Buske, C.; Ribrag, V.; Cunningham, D.; Jurczak, W.; Abrisqueta, P.; Li, J.; Gorbatchevsky, I.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • The genomic and transcriptomic landscape of double-refractory multiple myeloma
    Meeting Abstract

    Ziccheddu, B.; Biancon, G.; De Philippis, C.; Bagnoli, F.; Maura, F.; Dugo, M.; Devecchi, A.; De Cecco, L.; Sensi, M.; Terragna, C.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Phase 1 dose-finding study investigating CA-4948, an IRAK4 kinase inhibitor, in patients with R/R NHL: Report of initial efficacy and updated safety information
    Meeting Abstract

    Younes, A.; Nowakowski, G.; Rosenthal, A. C.; Leslie, L. A.; Tun, H. W.; Lunning, M. A.; Isufi, I.; Martell, R.; Patel, K.
    Blood (2019)

    Fulltext@MSK | Save
  • A multi-center dose-finding study to assess safety, tolerability, pharmacokinetics and preliminary efficacy of fimepinostat (CUDC-907) in combination with venetoclax in patients with relapsed/refractory (R/R) lymphoma
    Meeting Abstract

    Younes, A.; Batlevi, C. L.; Cohen, J. B.; de Vos, S.; Landsburg, D. J.; Myint, Z. W.; Patel, K.; Phillips, T. J.; Smith, S. M.; Westin, J. R.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Increased number of high dose methotrexate cycles and the addition of rituximab is associated with better outcomes in a large primary CNSL cohort
    Meeting Abstract

    Yerram, P.; Reiss, S. N.; Modelevsky, L.; Schaff, L.; Reiner, A.; Panageas, K.; Grommes, C.
    Blood (2019)

    Fulltext@MSK | Save
  • Safety and efficacy of atezolizumab in combination with rituximab plus CHOP in previously untreated patients with diffuse large B-cell lymphoma (DLBCL): Updated analysis of a phase I/II study
    Meeting Abstract

    Younes, A.; Burke, J. M.; Cheson, B. D.; Diefenbach, C.; Ferrari, S.; Hahn, U. H.; Hawkes, E. A.; Khan, C.; Lossos, I. S.; Musuraca, G.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Highly favorable outcomes with salvage radiation therapy followed by autologous transplant in relapsed and refractory DLBCL patients with minimal or no response to salvage chemotherapy
    Meeting Abstract

    Yang, J. C.; Chau, K.; Scordo, M.; Sauter, C. S.; Yahalom, J.
    Blood (2019)

    Fulltext@MSK | Save
  • Inotuzumab ozogamicin is an effective salvage therapy in relapsed/refractory B-cell acute lymphoblastic leukemia with high-risk molecular features, including TP53 loss
    Meeting Abstract

    Yang, X.; King, A. C.; Kabel, C. C.; Forlenza, C. J.; Park, J. H.; Geyer, M. B.
    Blood (2019)

    Fulltext@MSK | Save